EFFLUVIUM AS A SEQUEL TO COVID-19 TELOGEN

Abstract:

At the beginning of January 2020, the World Health Organization-WHO named SARS-CoV-2 a new virus discovered in Wu-han, China at the end of 2019 and that causes COVID-19. The disease spread rapidly throughout the city and spread to the country and the rest of the world, causing it to be declared a pandemic in March 2020. With this announcement, the entire world was affected by the restrictions that several countries implemented in order to stop the rate of infection. As the disease is being investigated and better characterized, several symptoms have been recorded that can be attributed to previous infection with this virus. This is the case of telogen effluvium, which has been characterized as a sequel to COVID-19, occurring an average of 1.5 months after the initial infection. This work will describe telogen effluvium as a pathology, its clinical manifestations and possible causes, taking into account into account its role as a new sequel described for the COVID-19 disease.

Año de publicación:

2022

Keywords:

• telogen effluvium
• covid-19
• dermatological diseases
• viruses

Fuente:

scopus